期刊
STROKE
卷 45, 期 1, 页码 281-283出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/STROKEAHA.113.003352
关键词
acute treatment; brain swelling; cerebral edema; glyburide; hemorrhagic transformation; ischemic stroke
资金
- Remedy Pharmaceuticals, Inc.
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082517] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK079637] Funding Source: NIH RePORTER
Background and Purpose Preclinical and retrospective clinical data indicate that glyburide, a selective inhibitor of sulfonylurea receptor 1-transient receptor potential melastatin 4, is effective in preventing edema and improving outcome after focal ischemia. We assessed the feasibility of recruiting and treating patients with severe stroke while obtaining preliminary information on the safety and tolerability of RP-1127 (glyburide for injection). Methods We studied 10 patients with acute ischemic stroke, with baseline diffusion-weighted imaging lesion volumes of 82 to 210 cm(3), whether treated with intravenous recombinant tissue-type plasminogen activator, age 18 to 80 years, and time to RP-1127 10 hours. Results Recruitment was completed within 10 months. The mean age was 50.5 years, and baseline diffusion-weighted image lesion volume was 10223 cm(3). There were no serious adverse events related to drug and no symptomatic hypoglycemia. The increase in ipsilateral hemisphere volume was 5033 cm(3). The proportion of 90-day modified Rankin Scale 4 was 90% (40% modified Rankin Scale, 3). Conclusions RP-1127 at a dose of 3 mg/d was well tolerated and did not require any dose reductions. A clinical trial of RP-1127 is feasible. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT01268683.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据